MODERN TREATMENT OF HERPES VIRUS INFECTION AND PROBLEMS OF RESISTANCE TO ANTIVIRAL DRUGS

Authors

  • Abdurakhmonova K.R., Dusiyorova M.S. Assistant of the Department of Microbiology, Virology and Immunology, TDTU,Student of the 1st Faculty of Medicine, TDTU

DOI:

https://doi.org/10.5281/zenodo.20514387

Keywords:

Herpes simplex virus, HSV-1, HSV-2, antiviral therapy, acyclovir, valacyclovir, famciclovir, antiviral resistance, latent infection, relapse, CRISPR-Cas9, therapeutic vaccines, immunomodulation, epigenetic therapy, mRNA vaccines, herpetic encephalitis, neonatal herpes

Abstract

 This article comprehensively analyzes modern treatment methods for infections caused by Herpes simplex virus (HSV-1 and HSV-2), the problem of antiviral drug resistance, and promising therapeutic approaches. Herpes infection is one of the most widespread chronic viral diseases worldwide, characterized by the lifelong persistence of the virus in nerve ganglia in a latent state, which significantly complicates complete eradication of the infection. The article discusses the mechanisms of action, clinical efficacy, and principles of use of major antiviral drugs such as acyclovir, valacyclovir, and famciclovir, as well as issues related to the emergence of resistant viral strains. In addition, modern scientific data on immunomodulators, therapeutic vaccines, mRNA technologies, CRISPR-Cas9 genome editing systems, epigenetic regulation, and novel treatment strategies based on natural antiviral compounds are presented.

Downloads

Download data is not yet available.

References

1. American Academy of Pediatrics. Red Book: Herpes Simplex. 2021.

2. Aubert M, et al. In vivo disruption of latent HSV by CRISPR-Cas9. JCI Insight. 2016;1(14):e88684.

3. Bloom DC, Giordani NV, Kwiatkowski DL. Epigenetic regulation of HSV latency. J Virol. 2010;84(20):10454-10463.

4. CDC. Sexually transmitted infections treatment guidelines. MMWR. 2021.

5. Corey L, Wald A, Patel R, et al. Valacyclovir suppression of HSV-2 transmission. Ann Intern Med. 2004;140(9):668-674.

6. Fields BN, Knipe DM, Howley PM. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2021.

7. Gaby AR. Natural remedies for herpes simplex. Altern Med Rev. 2006;11(2):93-101.

8. Gebhardt T, Wakim LM, Eidsmo L, et al. Memory T cells in tissue immunity. Nat Rev Immunol. 2009;9(10):695-704.

9. Griffith RS, Norins AL, Kagan C. Lysine therapy in herpes simplex infections. Dermatologica. 1987;175(4):183-190.

10. Kimberlin DW, Whitley RJ. Neonatal herpes. N Engl J Med. 2005;353(17):1809-1816.

11. Koch C, Reichling J, Schneele J, Schnitzler P. Antiviral activity of flavonoids against HSV. Antiviral Res. 2021;192:105102.

12. Piret J, Boivin G. Antiviral resistance in herpes simplex virus infections. Curr Opin Infect Dis. 2016;29(6):654-662.

13. Roizman B, Knipe DM, Whitley RJ. Herpes simplex viruses. Fields Virology. 7th ed. Wolters Kluwer; 2021.

14. Schnitzler P, Schuhmacher A, Astani A, Reichling J. Melissa officinalis oil against HSV infection. Phytomedicine. 2008;15(9):734-740.

15. Spruance SL, Tyring SK, DeGregorio B, et al. Famciclovir for recurrent HSV infection. Antimicrob Agents Chemother. 1997;41(2):359-365.

16. Srivastava R, et al. Therapeutic vaccines for HSV infection. Hum Vaccin Immunother. 2019;15(10):2414-2428.

17. van Diemen FR, Lebbink RJ. CRISPR-Cas systems for herpesvirus infections. Curr Opin Virol. 2021;50:45-52.

18. Wald A, Timmler B, Magaret A, et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. N Engl J Med. 2014;370:201-210.

19. Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357(9267):1513-1518.

20. World Health Organization. Herpes simplex virus. Fact sheet. 2023

21. Piperi, E., Papadopoulou, E., Georgaki, M., Dovrat, S., Bar Illan, M., Nikitakis, N. G., & Yarom, N. (2024). Management of oral herpes simplex virus infections: The problem of resistance. A narrative review. Oral Diseases, 30, 877–894. https://doi.org/10.1111/odi.14635

Downloads

Published

2026-06-02

Issue

Vol. 5 No. 6 (2026): Journal of Multidisciplinary Sciences and Innovations

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

How to Cite

MODERN TREATMENT OF HERPES VIRUS INFECTION AND PROBLEMS OF RESISTANCE TO ANTIVIRAL DRUGS. (2026). Journal of Multidisciplinary Sciences and Innovations, 5(6), 13-18. https://doi.org/10.5281/zenodo.20514387

Similar Articles

21-30 of 649

You may also start an advanced similarity search for this article.